Cell Reprogramming & Therapeutics LLC has received Wisconsin Small Business Innovation Award for Outstanding Achievements from The Center for Technology Commercialization of Wisconsin 2016 (www.wisconsininnovationawards.com).

Cell Reprogramming & Therapeutics LLC has received  SBIR Advance Grant-matching Award to support the commercialization of innovations, (https://www.wisconsinsbir.org), 2016-2017.

Cell Reprogramming & Therapeutics LLC (PI Arshak R Alexanian) has received NIH (NIA) grant supplement award (I-Corps, 2017) to support entrepreneurial training. The goal of the I-Corps™ Program is to accelerate the translation of biomedical research to the marketplace by providing training to SBIR grantees in the areas of innovation and entrepreneurship. 

Kick-Off Workshop: April 23-26, Hyatt Regency La Jolla, San Diego, California 

​Closing Workshop: June 12-13, 2017 Bethesda, Marriott, Bethesda, MD 

Awards & Achievements

Arshak R Alexanian, VMD, PhD, Founder and Chief Scientific Officer of Cell Reprogramming & Therapeutics LLC has received a prestigious scientific grant from the National Institutes of Health (NIH) (2015-2017). The grant was awarded for his breakthrough work  in the field of stem cell research and therapy. Recently, using a chemical genetics approach to stem cell reprogramming, Dr Alexanian has been able to generate dopaminergic neural cells from human mesenchymal stem cells (hMSCs) derived from bone marrow or fat. The current studies focus on developing processes for clinical grade manufacturing of these dopaminergic neural cells and testing their therapeutic effect in several preclinical animal models of Parkinson's disease.

Cell Reprogramming & Therapeutics LLC (PI Arshak R Alexanian) in collaboration with Mayo Clinic (subcontract) has received a prestigious scientific grant from the National Institutes of Health (NIH, National Cancer Institute) (2018-2019). In previous studies, Dr Alexanian has demonstrated that neural progenitor cells (NPC), generated from bone marrow or adipose tissue derived MSCs,  exhibited high migratory ability towards gliomas in vitro, and this tropism can be further enhanced by preconditioning these stem cells with glioma conditioned media (GCM). The goals of this SBIR phase I proposal are to investigate the in vitro tropism of these chemical induced and GCM primed NPCs to different glioma cells lines when they loaded with anti-glioma agent (Aim 1) and to test whether they can be utilized as vehicles for delivery of anti-glioma agent to intracranial human glioma xenografts in rodents (Aim 2).